OSLO (Reuters) - Norwegian authorities will buy the rare-disease
treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a
cost of 7 million Norwegian crowns ($880,381.33) per year per
patient, public broadcaster NRK reported on Monday.
Spinraza treats the rare, often fatal disease spinal muscular
atrophy (SMA). Norwegian authorities will cover the costs for minors
only.
($1 = 7.9511 Norwegian crowns)
(Reporting by Gwladys Fouche, editing by Terje Solsvik)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |